Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 93.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 94,990 shares of the insurance provider's stock after acquiring an additional 45,839 shares during the period. Caisse DE Depot ET Placement DU Quebec owned 0.08% of Humana worth $25,134,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in HUM. Cary Street Partners Investment Advisory LLC lifted its position in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares in the last quarter. Applied Finance Capital Management LLC grew its stake in Humana by 1.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider's stock valued at $779,000 after buying an additional 48 shares during the last quarter. Achmea Investment Management B.V. grew its stake in Humana by 0.5% in the 1st quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider's stock valued at $2,746,000 after buying an additional 49 shares during the last quarter. Beech Hill Advisors Inc. grew its stake in Humana by 6.1% in the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider's stock valued at $229,000 after buying an additional 50 shares during the last quarter. Finally, Townsquare Capital LLC grew its position in shares of Humana by 2.8% during the 1st quarter. Townsquare Capital LLC now owns 2,255 shares of the insurance provider's stock worth $597,000 after purchasing an additional 61 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on HUM shares. Robert W. Baird decreased their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Bank of America dropped their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Wells Fargo & Company dropped their price target on shares of Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Finally, Piper Sandler decreased their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Seven investment analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $283.29.
Read Our Latest Stock Analysis on Humana
Humana Stock Performance
HUM stock traded up $6.01 during mid-day trading on Friday, hitting $303.90. The company had a trading volume of 1,099,760 shares, compared to its average volume of 1,399,323. The stock's fifty day moving average price is $254.43 and its two-hundred day moving average price is $254.62. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $382.72. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market cap of $36.55 billion, a PE ratio of 23.32, a price-to-earnings-growth ratio of 1.75 and a beta of 0.44.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period last year, the firm earned $6.96 EPS. The business's revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana's payout ratio is currently 27.17%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories

Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.